Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
GLP-1 receptor agonists — best known for treating diabetes and obesity — may also protect against multiple sclerosis flares. A large U.S. real-world study found MS patients on GLP-1 drugs had significantly lower rates of relapses, optic neuritis, and demyelinating events over 12 years. Researchers believe these drugs may curb neuroinflammation through the gut-brain axis, though prospective trials are still needed.
GLP-1 receptor agonists — the class of drugs behind blockbusters like semaglutide and liraglutide — may have a surprising new role: protecting the brains of people with multiple sclerosis. A large real-world U.S. study presented at MSToronto2026 found that MS patients exposed to GLP-1 drugs had significantly lower rates of relapses, optic neuritis, demyelinating events, gait problems, fatigue, and depression compared to those who didn't use them — over a 12-year observation window.
The study used the TriNetX research network and included over 339,000 MS patients, with 14,300 exposed to GLP-1 agents. Propensity-score matching was applied to control for age, sex, and comorbidities. Benefits were also seen in a subgroup of patients on the B-cell therapy ocrelizumab, with the greatest risk reduction in steroid-treated relapses. Researchers suggest GLP-1 drugs may modulate neuroinflammation and support neuronal survival via the gut-brain axis.
By the Numbers:
Why it matters: These findings open a compelling new avenue for GLP-1 drugs beyond metabolic disease. If confirmed in prospective trials, they could represent a meaningful add-on neuroprotective strategy for MS patients — many of whom already qualify for GLP-1 therapy due to obesity or diabetes.
